Erratum for Reitzel et al., “Minocycline-EDTA-Ethanol Antimicrobial Catheter Lock Solution Is Highly Effective *In Vitro* for Eradication of *Candida auris* Biofilms”

Ruth A. Reitzel,^a Joel Rosenblatt,^a Bahgat Z. Gerges,^a Nylev Vargas-Cruz,^a Issam I. Raad^a

^aDepartment of Infectious Diseases, Infection Control, and Employee Health, University of Texas MD Anderson Cancer Center, Houston, Texas, USA

Volume 64, no. 4, e02146-19, 2020, <https://doi.org/10.1128/AAC.02146-19>. The following paragraph should be included at the end of the article text:

ACKNOWLEDGMENTS

I. I. Raad and J. Rosenblatt are inventors of the minocycline-EDTA-ethanol catheter lock solution technology which is owned by the University of Texas MD Anderson Cancer Center (UTMDACC) and has been licensed to Novel Anti-Infective Technologies, LLC, in which Drs. Raad and Rosenblatt and UTMDAAC are shareholders, and has been sublicensed to Citius Pharmaceuticals Inc., for whom Dr. Raad is a scientific advisor and shareholder and Dr. Rosenblatt is a consultant and shareholder.

Citation Reitzel RA, Rosenblatt J, Gerges BZ, Vargas-Cruz N, Raad II. 2020. Erratum for Reitzel et al., “Minocycline-EDTA-ethanol antimicrobial catheter lock solution is highly effective *in vitro* for eradication of *Candida auris* biofilms.” Antimicrob Agents Chemother 64:e01014-20. <https://doi.org/10.1128/AAC.01014-20>.

Copyright © 2020 American Society for Microbiology. All Rights Reserved.

Address correspondence to Ruth A. Reitzel, ruth.reitzel@gmail.com.

Published 23 June 2020